FDA staff: NPS drug effective; no significant safety imbalance

September 10, 2014 3:17 PM

6 0

FDA staff: NPS drug effective; no significant safety imbalance

WASHINGTON (Reuters) - NPS Pharmaceuticals Inc's hormone replacement therapy Natpara reduced the need for calcium and vitamin D supplements in clinical trials, though some data was excluded due to manufacturing violations, according to a preliminary review by the U.S. Food and Drug Administration.

NPS shares gained 15 percent in pre-market trading to $29.40 from a close of $25.77, returning to levels it was trading at on Sept. 4 before investors grew concerned that the FDA documents would contain negative information about the treatment.

Read more

To category page

Loading...